Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which could finally unlock the drug’s potential in the US. Top-line data from the two ...
Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known as eczema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback